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2 
Abstract  
 
Caspase-6 (CASP6) has emerged as an important player in Huntington disease (HD), Alzheimer disease 
(AD) and cerebral ischemia, where it is activated early in the disease process. CASP6 also plays a key role in 
axonal degeneration, further underscoring the importance of this protease in neurodegenerative pathways. As 
a protein’s function is modulated by its protein-protein interactions we performed a high throughput yeast-2-
hybrid (Y2H) screen against ~17,000 human proteins to gain further insight into the function of CASP6. We 
identified a high confidence list of 87 potential CASP6 interactors. From this list, 61% are predicted to 
contain a CASP6 recognition site. Of nine candidate substrates assessed, six are cleaved by CASP6. Proteins 
that did not contain a predicted CASP6 recognition site were assessed using a LUMIER assay approach and 
51% were further validated as interactors by this method. Of note, 54% of the high-confidence interactors 
identified show alterations in human HD brain at the mRNA level, and there is a significant enrichment for 
previously validated huntingtin (HTT) interactors. One protein of interest, STK3, a proapoptotic kinase, was 
validated biochemically to be a CASP6 substrate. Furthermore, our results demonstrate that in striatal cells 
expressing mutant huntingtin (mHTT) an increase in full length and fragment levels of STK3 are observed. 
We further show that caspase-3 is not essential for the endogenous cleavage of STK3. Characterization of the 
interaction network provides important new information regarding key pathways of interactors of CASP6 and 
highlights potential novel therapeutic targets for HD, AD and cerebral ischemia. 
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3 
Introduction 
 
Apoptosis, a genetically programmed form of cell death that utilizes caspases, is a fundamental biological 
process essential for development and regulating the delicate balance between life and death in cells. In 
neurodegenerative diseases, alterations in components of the cell death machinery occur and enhance 
apoptosis (reviews (1-3)). Alterations in key components of this death cascade can also have opposite effects 
and cause uncontrolled cell growth or cancer (reviews (4, 5)). Caspases post-translationally modify their 
substrates through cleavage at specific recognition sites and cause either inactivation of the protein or a gain 
of function through generation of active proteolytic fragments. Activation of caspases and proteolytic 
cleavage of specific caspase substrates is an early, critical cellular event in several neurodegenerative 
diseases and ischemic brain disorders (6-23). Corroborating their role in neurodegeneration, inhibiting 
caspases improves neuronal health and behavioral outcomes in models of neurological disease (24-26). 
Furthermore, environmental enrichment strategies that delay and/or decrease cognitive deficits due to 
neurological abnormalities are associated with a decrease in caspase expression levels in the brain (27, 28). 
In contrast, aging, that is characterized by a decline in learning and memory capacity, is accompanied by 
increased levels of some caspases (15, 17, 29). 
 
Huntington disease (HD), a fatal neurodegenerative disorder characterized by progressive deterioration of 
cognitive and motor functions, is caused by an expansion of a trinucleotide (CAG) repeat encoding glutamine 
in the N-terminus of huntingtin (HTT) (30). Neurodegeneration in HD occurs initially and most severely in 
the medium spiny neurons of the striatum, and later in the deep layers of the cortex (31). In addition to 
caspase activation, a long-standing hypothesis in neurological disorders such as HD and AD also proposes 
excitotoxic stress as a key mechanism underlying the pathogenesis of these diseases (6, 8, 10, 32-41). 
Importantly, HD and AD share a striking number of other similarities including psychiatric symptoms and 
cognitive dysfunction, increased age-associated risk, neurotrophin depletion and abnormal protein folding 
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4 
(42). Recently, links between excitotoxic pathways, activation of specific caspases and behavioral deficits 
have been identified. The evidence suggests that proteolysis of particular caspase substrates may amplify the 
excitotoxic response and trigger activation of neuronal cell dysfunction, behavioral abnormalities and 
eventual cell death (6-10, 15, 43). A critical role for excitotoxic stress and caspase activation has also been 
demonstrated in several models of ischemia (18-20, 22, 23). Indeed, studies of patients, experimental animals 
and cell culture models in AD, HD and cerebral ischemia provide strong evidence of potential universal 
mechanisms in the early stages of pathways leading to neuronal death (reviews (1, 2, 42)). 
 
A deeper understanding of caspase substrates and the function of the proteolytic fragments produced upon 
cleavage is critical for elucidating the mechanism(s) underlying activation of specific apoptotic pathways. 
Numerous caspase substrates, and the fragments generated post cleavage, have active roles in apoptosis. 
Indeed, in several experimental paradigms, stress-induced generation of caspase-cleaved proteolytic 
fragments has been shown to trigger toxicity and amplify the cell death response (44-52). Additional 
evidence supporting the role of caspase-generated fragments in the pathogenesis of neurodegenerative 
diseases derives from studies on the caspase resistant form of a caspase substrate. In general, inhibiting the 
proteolysis of a caspase substrate has been shown to provide protection against cell dysfunction and death (6-
8, 14, 15, 43, 49, 51, 53-64). 
 
CASP6 was originally identified as an executioner caspase due to its role in cytoskeletal alterations and 
cleavage of nuclear lamins. However, CASP6 has since been shown to also function as an initiator caspase 
through its ability to cleave initiator and executioner caspases (65-67) and activation of CASP6 is observed 
with aging in the brain and prior to the clinical and pathological diagnosis of both AD and HD (15, 17, 68, 
69). Furthermore, preventing CASP6 proteolytic processing of mutant huntingtin (mHTT) or amyloid 
precursor protein (APP) in HD and AD, respectively, or targeted deletion of CASP6 has been beneficial in 
these conditions (6-13, 15, 43, 70-72), suggesting that cleavage of other CASP6 substrates may play an 
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important role in the neurodegeneration observed in these disorders. A role for caspase cleavage (by caspase-
7) is also implicated in Spinocerebellar ataxia type 7 (73). 
 
Despite the wealth of evidence demonstrating a central role for CASP6 in neurodegenerative diseases, there 
has been no systematic study using a high-throughput unbiased approach to identify the CASP6 interactome. 
To date some CASP6 interactors have been identified, the vast majority are substrates by previous 
implication in an apoptotic/disease pathway and cleavage site assessment studies (review (1)). There are thus 
limited details regarding how CASP6 activation leads to neuronal dysfunction and cell death in 
neurodegenerative diseases. Here we report the first high-throughput study to determine the interacting 
proteins of the pro and active forms of a caspase. Delineating the global protein-protein interaction (PPI) 
network of CASP6 and linking proteins with known cellular functions to CASP6 provides important 
information regarding a key pathway involved in the pathogenesis of neurodegenerative diseases and 
highlight potential novel therapeutic approaches for HD, AD and ischemia. 
 
Results 
 
Y2H identification of the PPI network for caspase-6 
 
In order to identify CASP6 interactors we performed an automated Y2H screen. Plasmids were engineered to 
produce fusion proteins containing the LexA DNA binding domain and human CASP6 proform (p34) or 
active forms (p20 and p10) and then transformed into the MATa Y2H bait strain. Constructed bait strains 
were then systematically and individually mated with MATα Y2H prey strains carrying GAL4 activation 
domain fusion constructs of ~17,000 human sequence-validated non-redundant cDNAs from the human 
ORFeome collection (74, 75). Both the proform and active forms of the CASP6 protein were screened in 
order to provide additional information about a potential role of the identified substrates and possible 
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6 
regulators of CASP6. After mating in a matrix assisted approach, protein interactions were identified by yeast 
growth competence on selective SD4 plates as well as β-galactosidase activity. Potential false positive 
interactors were excluded from the results based on a list of proteins that show up in high frequency in 
previous screens with diverse bait proteins. We also excluded interactors that frequently provided a signal 
with different other bait proteins included in the screening campaign the CASP6 constructs were part of. 
Based on that a high confidence list of CASP6 interactor proteins was generated which includes 87 proteins 
that were positive in all three replica of the screen for growth competence under selective conditions and in 
addition were positive at least twice in the LacZ assay (Fig.1A,B, Sup. Table 1). Of the proteins identified as 
CASP6 interactors, 30 (34%) bind to all three CASP6 baits (p34, p20 and p10). Additionally, 24 (28%) of the 
proteins interacted with both p20 and p10 active forms of CASP6 (Fig.1C). Assessment of CASBAH and 
MEROPS databases [of caspase substrates] revealed that none of the identified 87 interactors were 
previously described CASP6 substrates with the exception of HTT(6, 54) and CASP6 itself (through 
autoactivation (76)). We also assessed the list in Panther (77) and GO databases to determine if there was any 
enrichment for specific functions and/or pathways. There was no over-representation after Bonferroni 
correction for function. However, there was a significant enrichment for proteins involved in the Insulin/IGF 
pathway-protein kinase B signaling cascade on the list of 87 interactors compared to a genome-wide 
reference list (p=0.002). Insulin receptors are a subgroup of receptor tyrosine kinases that are involved in 
modulating cell growth and metabolism.   
 
In order to determine if any of the CASP6 Y2H identified interactors contain possible CASP6 recognition 
sites we assessed the list through SitePrediction (78), a program that predicts the cleavage site of a protease 
of which some sites are already known. SitePrediction identified 53/87 interactors with one or more predicted 
CASP6 cleavage sites with 99.9% specificity (Fig.1C). Furthermore, 16/87 proteins are previously 
characterized disease-related proteins (OMIM database (79), Sup.Table.1). 
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7 
Validation of caspase-6 Y2H interactions by LUMIER 
 
Proteins identified in the CASP6 Y2H screen that did not contain a predicted CASP6 recognition site (28/87) 
were further validated using LUMIER, a luminescence-based, mammalian interaction assay (80) designed for 
the systematic mapping of dynamic protein-protein interaction networks. Six potential casp6 substrates were 
also included to provide additional validation of their interaction with casp6. Assessing the protein-protein 
interactions identified in the Y2H study in the LUMIER assay provides additional confidence that the 
interaction is high-quality, and, importantly observed in mammalian cells. All clones were tested twice in 
triplicate, and in both possible orientations of the Renilla and Firefly tags (Renilla bait-Fire-prey/Renilla 
prey-Fire-bait). We accepted an interaction as positive when it was observed at least in one of the two 
configurations, and when at least 2 experiments in the two repetitions were positive. The results of this 
experiment demonstrate that 51% of the interactions were confirmed by LUMIER (Fig.2). A similar success 
rate was also observed when a positive reference set of binary interactions from the literature was examined 
with the LUMIER assay (81), supporting our hypothesis that high confidence interactions were identified in 
our Y2H screens.  
 
HTT interacts with caspase-6 
 
We included several HTT fragment clones in the cDNA prey repertoire in order to determine if an interaction 
between HTT and CASP6 would be detected. As expected, and detected previously (82, 83), the LUMIER 
assay demonstrates that CASP6 interacts with fragments of wild type and mHTT (Sup.Fig.1). Both p34 and 
p20 identified the HTT clone HD507-1230 that contains the IVLD CASP6 recognition site. However, 
CASP6 also interacts with HTT fragments (HD513) that do not contain the 586aa putative CASP6 
recognition site suggesting that alternate binding sites for CASP6 are present in the N-terminal region of 
HTT as has been suggested by previous data (82). Furthermore, in the presence of the expanded 
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8 
polyglutamine tract, p34 no longer interacted with the HD513 fragment. CASP6 cleavage assays confirm that 
CASP6 interacts with HTT and generates an ~60 kDa HTT fragment that is detected with both MAB2166 
and BKP1 HTT antibodies (Fig.3A,B) consistent with previous findings (6, 54). It is important to note that 
even at the lowest concentration of recombinant CASP6 the 586aa HTT fragment is detected. Indeed, in our 
experimental paradigm, CASP6 cleaved HTT more efficiently than all other substrates assessed. 
Interestingly, there was a significant enrichment of HTT interactors in the list of potential CASP6 interactors. 
Fully 9/87 are described HTT interators (hypergeometric statistic = 5.6 x 10-8, Fig.3C). 
 
Identification of dysregulated caspase-6 interators in human HD brain 
 
In order to ascertain whether the identified potential CASP6 interactors may play a role in the pathogenesis 
of HD we first assessed if expression levels of the genes identified in the screen are altered in human HD 
post mortem brain tissue (grade 1-4) using previously published HD mRNA profiles generated through 
microarray analysis (84, 85). Of the 87 high-confidence interactors identified, 54% are either up (36%) or 
down (18%) regulated at the mRNA level in human HD brain compared to control tissues (Fig.3C, 
Sup.Table.2). Of note, of the genes dysregulated, 14 are altered in grade 1 post mortem HD brain. We then 
performed a function enrichment analysis using Panther (77) on the CASP6 interactors showing alterations in 
expression levels in human HD vs. control brain. A significant over-representation of the following pathways 
is observed: Insulin/IGF pathway-protein kinase B signaling cascade (p=0.002), p53 pathway feedback loops 
2 (p=0.02) and PI3 kinase pathway (p=0.02).  
 
We next determined if any novel and/or previously identified CASP6 interactors showed specific alterations 
in the caudate nucleus, the region most affected in HD using the INFIDEX method (86). By applying a 3-step 
expression data filtering strategy (see methods) to all direct interaction partners of CASP6, we identified a 
caudate nucleus-specific HD network. In the first step, 21 of 121 CASP6 interactors were shown to be 
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9 
differentially expressed in human brain compared to non-brain tissue and of those, 15 were differentially 
expressed in the caudate. Lastly, we assessed the 15 caudate specific CASP6 interactors to determine which 
were dysregulated in HD post mortem tissue compared to controls. Using this step-by-step approach we 
identified a caudate nucleus-specific HD network comprising 6 dysregulated CASP6 interaction partners 
namely STK3, VIM, TOP1, PKC, CFLAR, RIMS3 (Sup.Fig.2).  
 
Identification of novel caspase-6 substrates 
 
As CASP6 is activated early in HD, cleavage of other CASP6 substrates in addition to HTT, may contribute 
to the pathogenesis of HD. Cleavage may result in inactivation of the protein, for example of a pro-survival 
protein, and reduce the threshold for apoptosis to occur. Cleavage may also result in generation of toxic (pro-
apoptotic) fragments, which may then contribute to neuronal dysfunction and/or cell death. 
 
From our list of 87 interactors, 24 (28%) of the proteins were identified with both the p20 and p10 active 
forms of CASP6. In contrast, only 3 (3%) proteins are in common amongst the p34 proform of CASP6 and 
p10, and 2 (2%) amongst p34 and p20 baits supporting that some of these proteins may indeed be CASP6 
substrates.  
 
Bioinformatic approaches were used as a first step in order to prioritize the identification and characterization 
of possible CASP6 substrates involved in the pathogenesis of HD (Fig.4). The program SitePrediction (78), 
predicts that 53/87 CASP6 Y2H identified interactors contain at least one CASP6 cleavage site with 99.9% 
specificity, 51 of which are expressed in the brain. Subsequent to this, the list was further refined by only 
including genes implicated in the pathogenesis of HD (alteration in expression levels in human HD brain 
and/or previously identified HTT interactor) which gave a list of 32 proteins.  
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10 
In order to increase the likelihood of identifying substrates of CASP6, we chose only those proteins that 
interacted with both of the active forms of CASP6 (p20 and p10). Finally, in order to identify proteins 
potentially involved in key signaling pathways in HD, we determined which of the highlighted 21 proteins 
that bind to both active forms of CASP6 were involved in excitotoxic signaling pathways and/or apoptosis. 
Filtering the list in a systematic way highlighted the following 9 candidates (Table.1): Brain-specific 
angiogenesis inhibitor 1-associated protein 2 (BAIAP2), death domain associated protein (DAXX), Glycogen 
synthase kinase-3 alpha (GSK3A), palmdelphin (PALMD), phosphoinositide-3-kinase, regulatory subunit 1 
(alpha) (P13KR1), serine threonine kinase (STK3), RNA binging motif 17 (RBM17), syntaxin 16 (STX16) 
and ubiquitin specific peptidase (USP32). All candidate proteins are expressed in neurons and due to that a 
potential neuronal casp6 processing of these candidates might be disease relevant (Sup.Fig.3). This holds true 
even when the candidate mRNA might be preferentially expressed in another cell type. These proteins were 
then assessed to determine if they are true CASP6 substrates. 
 
Murine cortex lysates were subject to digestion with increasing concentrations of recombinant CASP6 for 
one hour or fixed concentration of CASP6 and varying times of incubation. Western blotting demonstrates 
that CASP6 cleaves DAXX (Fig.5A,B), STK3 (Fig.5C,D), USP32 (Sup.Fig.4A,B), PALMD (Sup.Fig.4C,D), 
RBM17 (Sup.Fig.5A,B) and STX16 (Sup.Fig.5C,D). Diagrams of each substrate are included which 
highlight structural domains and potential cleavage sites.  
 
Major CASP6 generated fragments observed for DAXX include 20, 30 and 60 kDa C-terminal fragments. 
For STK3 we observed two N-terminal fragments of 35 and 45 kDa, for USP32 N-terminal fragments of 80 
and 100 kDa, for PALMD 20 and 55 kDa C-terminal fragments, for RBM17 a 60 kDa fragment and for 
STX16 a 30 kDa fragment. All fragments detected contain the epitope for the antibody used and are of 
expected sizes based on SitePrediction with the exception of RBM17 and USP32. Cleavage by CASP6 would 
not generate an 80 kDa USP32 fragment based on SitePrediction predicted (99.9% specificity) cleavage sites. 
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11 
However it cannot be ruled out that another protease may cleave the CASP6 generated USP32 fragment thus 
resulting in a smaller sized fragment than expected. With regards to RBM17, no predicted sized fragments 
were observed. However, we did detect a band at ~70 kDa in size that is cleaved by CASP6. The predicted 
molecular weight of RBM17 is 45 kDa. However a form of this protein might run higher due to the acidic 
nature of this protein (pI 5.76) and/or the numerous phosphorylation sites (87). Indeed, 4 separate RBM17 
antibodies, which have different epitopes, detect the ~70 kDa band (see Methods). 
 
No cleavage fragments were detected post incubation with recombinant CASP6 for BAIAP2, GSK3A or 
PIK3R1 (Sup.Fig.6A-C). Overall CASP6 substrate validation of SitePrediction results had a success rate of 
67% but in each case SitePrediction did over-predict the number of CASP6 cleavage sites (Table.2). 
However, this does not exclude the possibility that some fragments may have high turnover rates, that the 
antibody did not recognize particular fragments and/or the concentration of recombinant CASP6 in our assay 
was insufficient for certain proteins.  
 
There are now 172 confirmed CASP6 interactors (Sup.Table.3). We included previously published, validated 
CASP6 interactors (review(1)) and considered preys from the high confidence list that interacted with at least 
one CASP6 bait in independent assays in both yeast and in mammalian cells as valid interactors. Performing 
Panther (77) analysis on this list reveals a significant over-representation of several key-signaling pathways 
post bonferroni correction including FAS signaling, HD, Apoptosis signaling, Gonadotropin releasing 
hormone receptor and AD-presenilin pathway. There is also a significant enrichment for certain molecular 
functions including structural constituents of the cytoskeleton, structural molecule activity, protein binding, 
cysteine-type peptidase activity and peptidase inhibitor activity, and protein classes including cytoskeletal 
proteins, intermediate filament, structural proteins, actin family cytoskeletal proteins and proteolysis (Table 
3). 
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12 
Alterations in STK3 observed in cellular model HD 
 
We next evaluated whether full length and/or fragment levels of the pro-apoptotic kinase STK3 demonstrate 
alterations in an acute model of HD. STK3 is a stress-activated pro-apoptotic kinase that upon activation and 
cleavage enters the nucleus and induces cell death pathways (88-90). We chose to focus on STK3 as 
alterations in its expression are observed in early grade human HD caudate (84, 85), caspase cleavage is 
required for activation and toxic fragments are translocated to the nucleus (90) [a key site of pathology in 
HD], and the fact that STK3 negatively regulates AKT(91) a key protein involved in the pathogenesis of HD 
(review(92)). Immortalized murine striatal cells with (STHdhQ111) and without (STHdhQ7) mHTT were serum 
starved and assessed for protein expression of STK3 using Western blotting (Fig.6A). Activation of CASP6 
is observed in this HD model (N. Skotte, personal communication) and is associated with increased cell death 
(93). A significant increase in full-length levels of STK3 is observed in striatal cells expressing mHTT 
compared to wild type (WT) at baseline (Fig.6B, ANOVA p=0.017, post-hoc p<0.05). Importantly, a 
significant increase in the 35kDa STK3 fragment levels is observed in neurons expressing mHTT compared 
to WT cells post serum starvation (Fig.6C, ANOVA p=<0.0001, post-hoc p<0.0001). Evaluation of lactate 
dehydrogenase (LDH) release (marker of cell death) demonstrates that cell death is observed with serum 
starvation in this model, consistent with previous findings (93) (Fig.6D, 3 h -serum vs. +serum p>0.05; 12 h 
post starvation, Q111, p<0.01).  
 
Cleavage of STK3 in the absence of caspase-3 
As caspase cleavage of STK3 has only been previously attributed to caspase-3 (CASP3) in the literature (90), 
we next wished to determine if cleavage of STK3 occurs in the absence of CASP3. We first show that both 
recombinant CASP3 and CASP6 generate the same ~35 kDa fragment, while cleavage with CASP6 
generates additional 40 and 45 kDa fragments (Fig.7A).  
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13 
Importantly, we show that cleavage of STK3 is observed in stressed MCF7 cells which do not contain 
CASP3 (94). Western blotting demonstrates that MCF7 cells stressed with camptothecin show a decrease in 
full-length STK3 levels and increase of STK3 fragments compared to unstressed MCF7 cells (Fig.7B). These 
data demonstrate that CASP6 is able to cleave STK3 and that under conditions of stress STK3 cleavage 
fragments are generated in the absence of CASP3. 
 
Discussion 
 
Substantial evidence supports a central role for CASP6 in neurodegenerative diseases (6-13, 15-17, 29, 47, 
48, 82, 95-97). Activation of CASP6 and not other caspases is observed before onset of motor abnormalities 
in human and murine HD brain and active CASP6 levels inversely correlate with age of onset of HD (15). 
Human AD brain also shows a significant increase in CASP6 mRNA (95) and active CASP6 (16, 17, 96). 
Furthermore, in human brain, levels of CASP6-cleaved-tau correlate with global cognitive scores 
emphasizing the early nature of CASP6 activation in the degenerative process of AD (17). It is crucial to 
understand the CASP6 network in order to identify victims and other key players in the cell death pathway. 
We identified 87 potential CASP6 interactors, 54% of which show alterations in mRNA expression in human 
HD brain, and we validated 6 novel CASP6 substrates. We further show that protein expression levels and 
cleavage of STK3, a novel CASP6 substrate identified, are altered in striatal cells expressing mHTT. 
 
In order to understand the dynamic nature of a protein and the pathways in which it is operative, it is 
important to have a more global view of its function in a biological system. Several innovative approaches, 
including LC-MS/MS and mRNA display, have been used to identify caspase interactors including substates 
(98-100). However, this is the first time that an Y2H and LUMIER screening approach has been employed 
using both the proform and the active form of a capase to identify a caspase interactome. In general overlap 
between Y2H and MS-based screens is low (~2-5%) suggesting method-specific biases exist and support 
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14 
studies to validate the interaction directly and/or use multiple methods as we have employed here. One 
explanation for the occurrence of false negatives in Y2H studies is the lack of the interaction domain in the 
prey since for numerous proteins only a section of the protein can be expressed. However this is not the case 
for our screen. Furthermore, the high stringent nature of the Y2H assay will mean that transient interactions, 
and/or proteins with low expression, may escape detection (101, 102). Also of consideration and a potential 
source of bias, is that some proteins may not fold properly in yeast, may require post translational 
modifications not found in yeast and/or an inability of interacting protein to enter the nucleus. It is important 
to note that our studies used human cDNA clones and we also performed the interaction assay in mammalian 
cells.  
 
Numerous caspase substrates have active roles in apoptosis, in particular as a result of the fragments 
generated post cleavage. Proteolytic cleavage of specific caspase substrates is an important cellular event in 
the pathogenesis of several neurodegenerative diseases (6-15, 17, 21). In HD, the CASP6 generated 586aa 
HTT fragment is observed in affected brain regions and a murine model expressing the 586aa mutant HTT 
fragment develops neurological abnormalities similar to those observed in HD mouse models (6, 103). 
CASP6 cleaved APP fragments are observed early in human AD brain (104) and processing of APP at this 
site generates a small peptide that is a potent inducer of apoptosis (97). In addition to APP, cleavage of 
several CASP6 substrates have been detected in human AD brain (48, 105, 106). As an example, p97, a 
valosin containing ubiquitin dependent ATPase, is cleaved by CASP6 in AD brain and the resultant fragment 
impairs the proteasome and destabilizes endogenous p97 (48). Importantly, CASP6-cleaved-tau (17, 107) and 
CASP6-cleaved p97 (48) are detected in mild cognitive impaired and AD human brains, suggesting that the 
activity of CASP6 precedes the clinical and pathological diagnosis of AD.  Of interest, CASP6 cleaved tau is 
observed in AD and HD brain (15, 17). Of note, inhibiting CASP6 cleavage of APP provides some protection 
in vivo against AD-like phenotype (9-13, 108) and eliminating cleavage at the 586aa CASP6 site of mutant 
HTT (C6R)  is sufficient to preserve neuropathological deficits and behavioral disturbances in a murine 
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model of HD (6-8, 15, 43) making CASP6 a potential target for therapeutic intervention in neurodegenerative 
diseases. The fact that the proform of CASP6 only interacts with the 513aa wild type htt fragment and not the 
mhtt fragment suggests that wild type htt may attenuate CASP6 activation but that mhtt is no longer able to 
perform this function. This notion is in line with the well-established neuroprotective properties of wild type 
htt. Indeed, while the mechanism(s) underlying the neuroprotective function of htt are poorly defined, a role 
for htt as a caspase inhibitor has been demonstrated (109, 110). It is interesting to speculate whether the loss 
of interaction between the proform of casp6 and mutant htt may contribute to the increased CASP6 activation 
in HD.  
 
To identify CASP6 interactors of high interest and their relationship to the disease state, we assessed our 
high-confidence list of CASP6 interactors to determine if any show alterations in HD human brain using 
microarray datasets previously published (84, 85). Interestingly a significant number show alterations in HD 
human brain. Of the potential interactors showing alterations, we observe an overrepresentation of the 
Insulin/IGF pathway-protein kinase B signaling cascade, p53 and PI3 kinase pathways. There are a number 
of proteins in common in these pathways including PDPK1, P13K3R1, PTEN, AKT and p53 all of which are 
implicated in the pathogenesis of HD (92, 111-116).  P53, a direct regulator of CASP6 (117), is a key protein 
involved in the cellular stress response and the p53 pathway connected by numerous negative and positive 
feed back loops including Wnt-beta-catenin, IGF-1-AKT, Rb-E2F, p38 MAP kinase, cyclin-cdk, p14/19 ARF 
pathways and cyclin G-PP2A, and p73 gene products (review (118)). The PI3 kinase pathway is also 
involved in several key biological processes including survival, metabolism and gene regulation 
(review(119)). 
 
We identified and validated several novel CASP6 substrates. DAXX has been previously implicated in 
stroke-mediated cell death and originally identified as a protein that binds to the death domain of the receptor 
FAS and potentiates FAS-induced apoptosis (120). Cleavage fragments of DAXX are pro-apoptotic and 
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activate the JNK pathway in an in vitro model (121). Multiple functions have been described including a role 
as a potent transcription repressor that binds to sumoylated transcription factors and as a suppressor of the 
neuroprotective protein kinase B (AKT) signaling pathway.mActivation of CASP6 and increases in DAXX 
are observed in a high glucose-induced apoptosis model (122). Cleavage of DAXX would interfere with its 
interaction with histone 3.3 due to disruption of its histone-binding domain and may lead to alterations in the 
deposition of histones on DNA and cause chromatin condensation. Proof of principle studies reveal a marked 
reduction in infarct size and apoptosis in ischemia induced cell death with knockdown and/or expression of a 
dominant-negative form of DAXX (120, 123). DAXX is also implicated in AD-mediated cell death (120). Of 
significance, robust increases in DAXX mRNA are observed in human AD brain (124, 125). DAXX 
destabilizes ASK1 causing release of GRX1 and TRX1, redox proteins that are involved in stabilizing ASK1 
and inhibiting the DAXX-ASK1-JNK toxic cell death pathway. Decreased protein expression of TRX1 is 
observed in human AD cortex and hippocampus, and overexpression of TRX1 in a cellular model of AD 
protects against Aß toxicity (126). A diagram of DAXX protein showing structural (coiled coil) and nuclear 
localization signal (NLS) motifs, and predicted CASP6 recognition sites is included as an example (Fig.5B). 
Strikingly, the predicted CASP6 recognition sites cluster around the structural and signaling motifs.  
 
Validated substrates also include RBM17 and USP32. Cleavage of RBM17, a protein involved in the 
splicesome complex, may interfere with its function in mRNA splicing thereby altering the regulation of 
alternative slicing on a global scale. As an example, the U2A-F homology motif, present in RBM17, 
mediates protein-protein interactions between factors involved in constitutive RNA splicing(127). Through 
this domain RBM17 regulates alternative splicing of the apoptosis regulatory gene FAS, a key player in PCD 
pathways. Importantly, splicing of FAS determines whether it encodes a pro-apoptotic or anti-apoptotic form 
of the FAS protein. RBM17 induces exon skipping of FAS resulting in production of the anti-apoptotic 
form(127). Significantly, in vitro generated fragments of RBM17 cannot bind an AG-containing RNA ligand 
(127). CASP6 cleavage of RBM17 may provide the mechanism whereby decreased regulation of FAS 
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through RBM17 causes a shift towards production of the pro-apoptotic from of FAS. USP32 is a ubiquitin 
protease and Ca++ binding protein know to be involved in protein degradation. In vitro generated fragments 
of USP32 have been shown to have alternate subcellular localizations suggesting possible alternate functions 
of the protein fragments(128).  
 
A number of serine threonine kinases play important roles in programmed cell death pathways and caspase 
cleavage of STK3 and STK4 is a known mechanism underlying amplification of the apoptotic response (90, 
129, 130). Indeed evolutionary conserved caspase sites in STK3 and STK4 hint at important biological roles 
for the fragments generated. Furthermore, STK3 and STK4 contain NES and NLS sequences (131) 
suggesting cleavage by caspases may alter the subcellular localization, substrate specificity and/or protein 
interactions of the fragments compared to the parent protein. CASP3 has been previously been shown to 
cleave STK3 and STK4, and CASP6 shown to cleave STK4 (90, 129, 130). Of note, particular fragments of 
STK4 demonstrate distinct catalytic activity and the function of fragments (pro-apoptotic) differ to that of the 
parent protein (89, 90). Specifically caspase cleavage removes the inhibitory C-terminal domain and the N-
terminal fragment is transported to the nucleus.  Importantly, in the context of the pathogenesis of HD, IGF-1 
inhibits STK3 cleavage and kinase activity via the PI3K/AKT pathway (91). Once STK3 kinase activity is 
activated via caspase cleavage (cleavage converts STK3 into constitutively active kinase), phosphorylation of 
c-Jun, H2B, JNK and p38 occurs and STK3 fragments localize to the nucleus prior to DNA fragmentation, 
suggesting additional nuclear functions of the STK3 fragments in apoptosis. STK3 is only the third kinase 
shown to interact with CASP6 (132, 133). However, in general caspases are targets of kinases and 
phosphatases, which facilitate exquisite calibration of caspase activation(134). Conversely, kinases can be 
targets of caspases, as in the case of RIPK1 and CASP6 (132), leading to inactivation of the kinase and 
termination of specific signaling pathways. 
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The evidence demonstrating CASP6 activation and cleavage of HTT and tau in HD mouse models, but not in 
the caspase-6-resistant HD mice (15) suggests that proteolysis of CASP6 substrates and generation of 
fragments plays a crucial role in the amplification of CASP6 activity and neuro-toxic signalling in HD. In 
both HD and AD alterations in AKT (a substrate of CASP6 (135)), including decreased expression and 
cleavage fragments are observed, suggesting decreased phosphorylation of STK3 may occur (136, 137).  
Furthermore, a decrease in IGF-1, a potent upstream activator of AKT, has also been reported in a cellular 
model of HD and may contribute to the downstream alterations in AKT and consequent effects (138). 
Microarray studies demonstrate that STK3 mRNA is significantly increased in early grade human HD brain 
(84). We demonstrate here that alterations in STK3 protein expression levels and post-translational 
modifications are detected in a cellular model of HD and caspase-mediated generation of STK3 fragments 
observed under conditions of stress in cells expressing mhtt. CASP6 now links STK3 and DAXX with AKT, 
JNK and histones in the pathogenesis of neurological disorders and highlights an early role for these 
substrates in neurodegenerative pathways. 
 
In conclusion, we have identified novel members of the CASP6 interactome and demonstrate that a number 
of these interactors are involved in key signaling pathways observed in neurodegenerative diseases. These 
data will empower future investigations into the role of caspases in neurodegenerative diseases and their 
potential as targets for therapeutic intervention.  
 
Material and Methods 
 
Yeast two-hybrid assay 
To create a prey-matrix for interaction mating, the MATα yeast strain L40ccα was individually transformed 
with pACT4-DM-based plasmids encoding prey proteins. The resulting yeast clones were arrayed in 384-
well microtiter plates. cDNA fragments encoding the bait protein fragments (CASP6_p10, CASP6_p20, 
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CASP6_p34) were subcloned into the yeast expression vector pBTM116-D9 and the resulting plasmids were 
transformed into the MATa yeast strain L40ccua. The activation of the reporter genes HIS3, URA3, and lacZ 
in autocativation tests as a result of the production of bait proteins were tested systematically. All three bait 
constructs were non-autoactive, and were taken for interaction mating assays with prey proteins (139). Liquid 
cultures of MATα yeast strains (preys) were replicated in 384-well microtiter plates using a pipetting robot 
(Tecan, Freedom EVOware®) and then mixed with bait protein producing MATa strains. For interaction 
mating, yeast mixtures were transferred onto YPD agar plates using a spotting robot (K4, KBiosystems) and 
incubated for 48 h at 30°C. After mating, clones were automatically picked from agar plates and transferred 
into 384-well microtiter plates containing SDII (-Leu-Trp) liquid medium and from there they were spotted 
onto SDII (-Leu-Trp) agar to select for diploid yeasts carrying both – bait and prey vectors. After incubation 
for 48 h at 30°C, diploid yeast clones were spotted onto SDIV (-Leu-Trp-Ura-His) agar to detect positive 
PPIs as well as on high density nylon membranes on top of SDIV agar plates for a LacZ assay. In the lacZ 
assay ß-galactosidase is produced just in growing cells in which bait and prey proteins interact. After 
incubation for 3 to 4 days at 30°C, grown colonies were fractured with liquid nitrogen and ß-galactosidase 
activity was detected using the X-Gal substrate. Digital images were taken from agar plates as well as from 
high density nylon membranes for Visual Grid software (GPC Biotech) assisted result digitalization. The 
automated Y2H screen was done in 4 repetitions. 
 
LUMIER assay 
For LUMIER assays protein A (PA)-Renilla luciferase (RL)-tagged fusion proteins were co-produced with 
firefly luciferase (FL)-tagged putative interactor proteins in HEK293 cells. After 48 h protein complexes 
were co-immunoprecipitated from cell extracts with IgG coated magnetic beads (Dynabeads®; Invitrogen); 
interactions between bait (PA-RL fusions) and prey proteins (FL fusions) were monitored by quantification 
of firefly luciferase activities (140). Quantification of Renilla luciferase activity was used to confirm that PA-
RL-tagged bait proteins are successfully immunoprecipitated from cell extracts. To detect Renilla and firefly 
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luciferase based luminescence in samples with fusion proteins the Dual-Glo Luciferase Kit (Promega) was 
used. Bioluminescence was quantified in a luminescence plate reader (TECAN Infinite M1000). For each 
interaction both PA-RL and FL interactor fusion combinations were tested. Further on, for each protein pair 
tested (interaction between selected bait and prey proteins) three different parallel co-immunoprecipitation 
experiments (Co-IPs A-C) were performed in HEK293 cells, in order to assess the specificity of an 
interaction. To investigate the interaction between the proteins X and Y the protein pairs (A) PA-RL-X/FL-
Y, (B) PA-RL/FL-Y and (C) PA-RL-X/FL were individually co-produced in HEK293 cells. The proteins 
PA-RL (fusions of protein A and Renilla luciferase) and FL (firefly luciferase) in experiments B and C were 
used as controls to examine background protein binding. The resulting protein complexes in Co-IPs A-C are 
systematically analyzed by quantification of firefly luciferase activity. R_op and R_ob binding ratios were 
obtained by dividing the firefly luminescence activity measured in sample A by activities found in samples B 
and C. These controls work to measure the protein interaction specificity. Low R_op values are an indication 
for unspecific prey protein interactions, while low R_ob values indicate unspecific bait protein interactions. 
Based on empirical studies with a set of well-characterized positive and negative interaction pairs (not 
shown), we defined that R_op and R_ob binding ratios of >1.5 indicate reliable, specific protein-protein 
interactions. 
 
Prediction of caspase-6 substrates 
Interactors were assessed for predicted caspase-6 cleavage sites using the SitePrediction web tool 
(HTTp://www.dmbr.ugent.be/prx/bioit2-public/SitePrediction/; REF). As SitePrediction requires protein 
identifiers (IDs) for input, the DAVID gene ID conversion tool (Accessed Jan 6, 2010; REF) was used to 
convert Entrez Gene IDs or GenBank IDs to Refseq protein IDs. The 87 interactors were mapped to 135 
Refseq IDs because each gene may map to one or more protein isoforms. These were submitted to 
SitePrediction (Accessed Jan 7, 2010) using the ‘caspase-6_Homo_sapiens_4_2’ cleavage model based on 
known human caspase-6 cleavage sites in the Merops database. Default parameters were used with the 
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‘extended statistics’ setting and a threshold of 70. An interactor was considered a putative caspase-6 substrate 
if at least one cleavage site was predicted with 99.9% specificity. 
 
Identification of HTT-CASP6 shared interactors 
To determine which caspase-6 Y2H interactors are known HTT interactors, we compared to HTT interactor 
publications (141-143). 
 
Genes dysregulated in human HD brain  
Direct interaction partners of CASP6 identified by the Y2H screen or known from the literature were 
identified as potentially perturbed in HD using a 3-step expression data filtering strategy. Gene expression 
analysis was carried out using the open source R software packages, available as part of the BioConductor 
project (www.bioconductor.org). The Gene Atlas data set was normalized using MAS5 (Affymetrix 
Microarray Suite 5). FDR (false discovery rate) values were computed using the local pooled error approach 
to identify significantly expressed genes (144). For the detection of dysregulated genes, we computed 
empirical Bayes moderated t-statistics, which corrects gene expression for the collection site, gender and age. 
For the three filtering steps we used two publicly available gene expression data sets [Gene Atlas (84, 145)]. 
In the first filtering step 21 of 121 CASP6 interactors were identified as being differentially expressed 
(adjusted p<0.00001) in human brain compared to non-brain tissues (adrenal gland, heart, kidney, liver, lung, 
lymph node, muscle, prostate, pancreas, placenta, salivary gland, thymus, thyroid, tonsil, testis, trachea, 
uterus, and uterine corpus) using the Gene Atlas data set (145). As pathogenesis in HD is brain region 
specific with neurons in the basal ganglia most severely affected (31), we next analyzed the 21 brain-specific 
CASP6 interactors for being differentially expressed (adjusted p<0.001) in the caudate nucleus (CN) 
compared to the motor cortex (MC), prefrontal cortex (PFC) and the cerebellum (CE) (84). 15 brain-specific 
interactors of CASP6 were also differentially expressed in the caudate nucleus. Finally, the caudate nucleus-
specific CASP6 interactors were filtered for genes differentially expressed in the caudate nucleus of HD 
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patient brains and healthy individuals. To define differentially expressed genes, expression profiles of brains 
of 44 HD patients and 36 healthy individuals were analyzed (84, 85). Only genes with p<0.001 were 
accepted as being differentially expressed in HD patients compared to controls. Using this step-by-step 
approach the caudate nucleus-specific HD network with 6 potentially dysregulated CASP6 interaction 
partners was predicted. 
 
Caspase-6 cleavage assays 
Five samples, each 30 µg of WT murine cortex protein lysates, were incubated with 0 nM, 30 nM, 300 nM, 
3 µM or 30 µM of CASP6 (Enzo Life Sciences, USA) at 37oC for 1 hour; another 4 samples (30 µg of WT 
cortex lysate) were incubated with 15 µM CASP6 at 37oC for 5 min, 15 min, 30 min or 60 min. Samples 
were then used for western blotting as described below. 
 
Cell culture and LDH assay 
The immortalized striatal neuronal cell lines STHdhQ7  and STHdhQ111 were cultured at 33°C in Dulbecco’s 
modified Eagle’s medium (DMEM, Gibco) supplemented with 10% fetal bovine serum, 100X Penicillin/ 
Streptomycin (Gibco), 2 mM L-glutamine (Gibco), and 0.5 mg/ml active G418. Cells were grown in a 
humidified atmosphere containing 5% CO2 and harvested using 0.25% trypsin-EDTA. For serum deprivation 
experiments, 600,000 cells were seeded on day one, medium was changed to serum free media on day 2 and 
cells harvested post 24 hours of starvation. MCF-7 cells were cultured in Dulbecco’s modified Eagle medium 
supplemented with 10% fetal calf serum and 2 mM L-Glutamine. Cells were stressed with 5 μM 
camptothecin for 16 h in the presence or absence of the caspase inhibitor Q-VD-OPh (1 mM) and harvested 
by scraping. 
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Protein analysis and Western blotting 
Murine cortical tissue lysates for CASP6 cleavage assays were homogenized in 0.303 M sucrose, 20 mM 
Tris-HCl pH 7.2, 0.5 mM EDTA and 1 mM MgCl2, without protease inhibitors using a glass-teflon IKA-RW 
15 homogenizer (Tekmar Company) at maximum speed and cleared by centrifugation for 5 min at 1300 g. 
Lysates were then run on SDS PAGE and probed with one of the following antibodies: DAXX (Santa Cruz: 
sc-7152) at 1:200, STK3 (Abcam: ab52641) at 1:2000, PI3RK1 (Abcam: ab90578) at 1:920, PALMD 
(ProteinTech Group: 16531-1-AP) at 1:800, USP32 (Abcam: ab86792) at 1:2000, RBM17 (ProteinTech 
Group: 13918-1-AP) at 1:1200, GSK-3α/β (Santa Cruz: sc-7291) at 1:500, BAIAP2 (ProteinTech Group: 
11087-2-AP) at 1:2000, STX16 (Proteintech) at 1:500, and Actin (Sigma) at 1:1000. Three additional 
RBM17 antibodies demonstrate an ~70 kDa band on the datasheet (ProteinTech Group: 15374-1-AP, 
GeneTex GTX120047 and Abcam ab101441). Cell lysates from immortalized striatal cultures were lysed in 
single detergent phosphatase (SDP) lysis buffer including protease inhibitors (50 mM Tris pH 8.0, 150 mM 
NaCl, 1% Igepal/NP40, 40 mM B-gp, 10 mM NaF, 1 mM NaVan, 1 mM PMSF, 5 µM zVAD, and 1X Roche 
Complete). Protein concentration was measured by DC protein assay kit (Bio Rad, USA). Lysates were then 
separated on 4-12% Bis-Tris gels (Invitrogen). Following transfer membranes were probed with STK3 
antibody and beta-tubulin (1:5000; T4026, Sigma Aldrich). Cell pellets from MCF-7 cultures were lysed in 
50 mM HEPES pH 7.4, 100 mM NaCl, 1% Igepal, 1 mM EDTA and 10% glycerol with 4.2 µM Pefabloc and 
‘Complete’ protease inhibitor cocktail (Roche) and protein concentrations determined. Following transfer the 
membrane was probed with anti-STK3 and anti-Actin antibodies. All immunoblots were prepared following 
standard procedures and used infrared-labeled secondary antibodies (1:5000; Rockland), Immobilon-PVDF-
FL membranes and the Li-Cor Odyssey Infrared imaging system (BioSciences). Quantitative analysis of 
immunoblotting was based on the integrated intensity from Li-Cor Odyssey software (v2.0). To assess serum 
starvation-induced cell death in the STHdhQ7  and STHdhQ111 , cells were seeded at 10,000 cells/well in a 96-
well plate in complete media. After 24 hours, serum starvation was induced by removing the complete 
media, washing once with PBS, and adding serum-free media. Control (non-serum starved) cells received 
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fresh complete media. 24 hours later, media was collected, centrifuged at 2,800 rpm for 4 min at 4 C to 
remove any cell debris, and the supernatant was collected for LDH activity measurements. The LDH assay 
was performed accordingly to the manufacturers instructions  (Roche Cytotoxicity Detection Kit). 
 
Statistical analysis 
Except where noted otherwise, statistical analysis was done using one-way and two-way ANOVA (in cases 
of significant effect of genotype, post-hoc comparisons between genotypes were performed using 
Bonferroni). P values, SEM, means and standard deviations were calculated using Graphpad Prism version 
6.0. Differences between means were considered statistically significant if p<0.05. 
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Legends for figures 
 
Fig.1 Results of Y2H screen with caspase-6. A) Pro-CASP6 exists as a dimer with a 23aa prodomain and 
14aa linker region between the large (p20) and small (p10) subunits. During activation each CASP6 
monomer is cleaved at 3 sites thereby removing the prodomain and linker region. B) The initial screen, 
including CASP6 baits p34 (proform), p20 (active form) and p10 (active form), was against a 16,945 human 
cDNA library. The secondary de-convolution screen included 1,066 cDNAs. Top hits (87 interactors) were 
observed in triplicate on SD4 screen and triplicate or duplicate on LacZ screen. C) Network view of protein-
protein interactions amongst CASP6 pro and active forms. The highest number of common interactions 
between CASP6 pro and active forms was observed between p34, p20 and p10 (34%). A large number of 
common interactions was also observed between p20 and p10 (28%).  
 
Fig.2 Confirmation of select caspase-6 Y2H identified interactors by LUMIER. Proteins identified in the 
CASP6 Y2H screen that did not contain a “predicted” CASP6 recognition site were further validated using 
LUMIER.  Six “predicted” CASP6 substrates were also included to provide additional validation of an 
interaction with CASP6. A total of 34 proteins were screened using LUMIER and 51% of the Y2H identified 
interactions confirmed. 
 
Fig.3 Several caspase-6 interacting proteins are dysregulated in HD brain. A) Murine cortex lysates 
were subject to digestion with increasing concentrations of recombinant CASP6 for one hour or fixed 
concentration of CASP6 (15μM) and varying times of incubation. Western blotting demonstrates that CASP6 
cleaves huntingtin using MAB2166 and B) BKP1 HTT antibodies. C) Network analysis demonstrates that a 
number of Y2H identified CASP6 interactors are involved in the pathogenesis of HD. Of the 87 interactors, 
47 (54%) are dysregulated in human HD brain at the mRNA level and 9 are HTT interactors. 
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43 
Fig. 4 Criteria for selecting potential caspase-6 substrates that may play a role in the pathogenesis of 
HD.  In order to prioritize characterization, and maximize the opportunity of identifying novel CASP6 
substrates involved in the pathogenesis of HD, Y2H identified proteins were assessed using the following 
criteria 1) high likelihood of cleavage by SitePrediction (99.9% specificity), 2) expressed in brain, 3) 
implicated in HD, 4) demonstrate an interaction with both p20 and p10 CASP6 baits, and 5) the biological 
function of the protein [implicated in excitotoxicity/signal transduction and/or apoptosis pathways]. The 
resultant proteins were then assessed in CASP6 cleavage assays. 
 
Fig.5 Novel CASP6 substrates STK3 and DAXX identified. Murine cortex lysates were subject to 
digestion with increasing concentrations of recombinant CASP6 for one hour or fixed concentration of 
CASP6 (15μM) and varying times of incubation. Western blotting demonstrates that CASP6 cleaves A) 
death domain associated protein (DAXX). B) Diagram of DAXX protein showing structural (coiled coil) and 
nuclear localization signal (NLS) motifs. CASP6 also cleaves C) serine threonine kinase (STK3). D) 
Diagram of STK3 protein showing structural (coiled coil), kinase domain and adenosine 5’ -triphosphate 
(ATP) motifs.  Major cleavage fragments are highlighted by arrows. FL=full length form of protein. 
‘Predicted’ CASP6 recognition sites are shown in blue.  
 
Fig.6 Alterations in expression levels and post-translational modifications of STK3 observed in acute 
and chronic models of HD. A) Immortalized striatal cells with (STHdhQ111) and without (STHdhQ7) mutant 
HTT were incubated ± serum and using Western blotting assessed at 24hrs post starvation for protein 
expression of STK3 (n=3). Controls include STHdhQ7 lysate ±CASP6. B) A significant increase in full length 
(FL) levels of the pro-apototic kinase, STK3, is observed in striatal cells expressing mutant HTT compared to 
WT at baseline (ANOVA p<0.017, post hoc STHdhQ7(+) vs. STHdhQ111(+) p<0.05). In contrast, FL levels of 
STK3 are decreased in STHdhQ111(-) compared to STHdhQ111(+) cells (post hoc p<0.05) as expected due to 
the cleavage of STK3. C) A significant increase in fragment levels of STK3 is observed in cells expressing 
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mutant HTT compared to WT post serum starvation (ANOVA p<0.0001, post hoc STHdhQ7(-) vs. 
STHdhQ111(-) p<0.001). D) Evaluation of cell death in serum starved STHdhQ7 and STHdhQ111 cells 
demonstrates that a significant increase in cell death is observed in STHdhQ111 cells 12 and 24hrs post 
starvation. Tubulin was used as a loading control. 
 
Fig.7 Cleavage of STK3 in the absence of caspase-3. Alterations in expression levels and post-translational 
modifications of STK3 are observed in stressed MCF7 cells. A) Incubation of murine cortex with either 
recombinant casp3 or CASP6 demonstrates that both caspase-3 and caspase-6 cleave STK3. However, 
caspase-3 generates a single cleavage fragment while in contrast caspase-6 generates 3 cleavage fragments of 
STK3. In addition, B) Western blotting demonstrates that MCF7 cells, which lack caspase-3, stressed with 
campothecin show a decrease in full-length STK3 levels and an increase in STK3 fragments compared to 
unstressed MCF7 cells. C) A significant decrease in full-length (FL) levels of STK3 is observed in in MCF7 
cells post camptothecin stress (n=4, p<0.001). D) Furthermore, a significant increase in STK3 fragment 
levels is observed in MCF7 cells post stress (n=4, p<0.001). In contrast, the STK3 fragment was not detected 
in stressed MCF7 cells pretreated with the pan caspase inhibitor Q-VD-OPh. Actin was used as a loading 
control. 
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Tables 
 
Table.1 Top CASP6 Y2H identified potential CASP6 substrates that may play a role in the 
pathogenesis of HD.  
 
Gene 
Symbol 
Dysregulated 
in human 
HD brain 
Excitotoxocity/Signal 
transduction 
Apoptosis 
BAIAP2 a    b    
GSK3A a    
STX16 a  b  c    
PALMD a    
P13KR1 a  b      
DAXX a      
STK3 a  b     
USP32 a     
RBM17 a  b      
aIn grade 1-4 human HD brain vs. control 
bIn grade 1 human HD brain vs. control 
cIn HD astrocytes vs. control 
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Table.2 Summary of CASP6 Y2H identified interactors assessed in CASP6 cleavage assays.  
 
Gene 
Symbol 
Predicted 
CASP6 sites 
[SitePrediction] 
Validated 
[cleavage 
assay] 
# cleavage 
fragments  
DAXX 15 YES 7 
PALMD 7 YES 4 
USP32 5 YES 3 
PIK3R1 5 NO 0 
RBM17 5 YES 1 
STK3 3 YES 2 
BAIAP2 2 NO 0 
STX16 2 YES 1 
GSK3A 1 NO 0 
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Table.3 Result of Panther analysis on validated CASP6 interactors 
 
Pathway p value Fold 
Enrichme
nt 
FAS signaling p=7.05E-10 >5 
HD p=1.94E-08 >5 
Apoptosis signaling p=3.84E-06 >5 
Gonadotropin releasing 
hormone receptor 
p=0.002 >5 
AD-presenilin p=0.004 >5 
Molecular function p value  
Structural constituents - 
cytoskeleton 
p=1.93E-11 4.9 
Structural molecule 
activity 
p=5.98E-09 3.6 
Protein binding p=2.03E-06 2.3 
Cysteine-type peptidase 
activity 
p=0.0003 >5 
Cytoskeletal protein 
binding 
p=0.004 >5 
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Peptidase Inhibitor 
activity 
p=0.003 >5 
Protein class p value  
Cytoskeletal p=9.36E-14 >5 
Anatomical structural p=1.79E-10 >5 
Metabolic process p=3.14E-07 1.6 
Intermediate filament p=5.74E-06 >5 
Actin cytoskeletal p=0.0005 4.4 
Proteolysis p=0.0004 3.2 
All values are post Bonferroni correction. 
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Abbreviations 
APP – Amyloid beta precursor protein 
BAIAP2 - Brain-specific angiogenesis inhibitor 1-associated protein 2  
CASP6 – Caspase-6 
CE – Cerebellum 
CN – Caudate nucleus 
DAXX - Death domain associated protein 
GSK3A - Glycogen synthase kinase-3 alpha 
HTT – huntingtin 
INFIDEX (interaction network filtering by differentially expressed genes) 
LDH – Lactate dehydrogenase 
MC – Motor cortex 
mHTT – mutant huntingtin 
PALMD - Palmdelphin  
PFC – Prefronal cortex 
P13KR1 - Phosphoinositide-3-kinase, regulatory subunit 1 (alpha)  
PPI – Protein-protein interaction 
RBM17 - RNA binging motif 17  
STK3 - serine threonine kinase  
STX16 - Syntaxin 16 
USP32 - Ubiquitin specific peptidase 
Y2H – Yeast-two-hybrid 
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